NASDAQ:TSRO - Tesaro Stock Price, Price Target & More

$51.73 -0.48 (-0.92 %)

(As of 04/20/2018 11:06 AM ET)

Previous Close$52.21

Today's Range$51.35 - $53.07

52-Week Range$50.67 - $168.92

Volume137,559 shs

Average Volume1.15 million shs

Market Capitalization$2.99 billion

P/E Ratio-5.73

Dividend YieldN/A

Beta1.34

About Tesaro (NASDAQ:TSRO)

Tesaro, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. The company also develops Niraparib for the treatment of various tumors. In addition, it is developing immunotherapy antibody product candidates, including TSR-042, which is in a phase I clinical trial targeting programmed cell death protein 1; TSR-022 that is in phase I clinical trial targeting T-cell immunoglobulin domain and mucin domain-3; and TSR-033, an antibody candidate, which is in phase I clinical trial targeting lymphocyte-activation gene-3. The company has collaboration and exclusive license agreement with AnaptysBio, Inc., as well as collaboration agreements with Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd., Merck Sharp & Dohme B.V., and Jiangsu Hengrui Medicine Co., Ltd. Tesaro, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Receive TSRO News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:TSRO

CUSIP88156910

Webwww.tesarobio.com

Phone339-970-0900

Debt

Debt-to-Equity Ratio1.75%

Current Ratio4.74%

Quick Ratio4.39%

Price-To-Earnings

Trailing P/E Ratio-5.73

Forward P/E Ratio-5.43

P/E GrowthN/A

Sales & Book Value

Annual Sales$223.33 million

Price / Sales12.69

Cash FlowN/A

Price / CashN/A

Book Value$4.58 per share

Price / Book11.29

Profitability

EPS (Most Recent Fiscal Year)($9.17)

Net Income$-496,120,000.00

Net Margins-222.15%

Return on Equity-126.44%

Return on Assets-67.17%

Miscellaneous

Employees715

Outstanding Shares54,800,000

How to Become a New Pot Stock Millionaire

Tesaro (NASDAQ:TSRO) Frequently Asked Questions

What is Tesaro's stock symbol?

Tesaro trades on the NASDAQ under the ticker symbol "TSRO."

How were Tesaro's earnings last quarter?

Tesaro (NASDAQ:TSRO) posted its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($3.35) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.39) by $0.96. The biopharmaceutical company had revenue of $48.02 million for the quarter, compared to the consensus estimate of $51.78 million. Tesaro had a negative net margin of 222.15% and a negative return on equity of 126.44%. View Tesaro's Earnings History.

When is Tesaro's next earnings date?

Tesaro is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Tesaro.

What price target have analysts set for TSRO?

23 analysts have issued twelve-month price targets for Tesaro's stock. Their forecasts range from $48.00 to $199.00. On average, they expect Tesaro's stock price to reach $129.2609 in the next year. View Analyst Ratings for Tesaro.

What are Wall Street analysts saying about Tesaro stock?

Here are some recent quotes from research analysts about Tesaro stock:

1. Cann analysts commented, "Tesaro released Q4 2017 results today with better than expected Zejula sales and higher than estimated R&D. Due to a certain amount of confusion and competition in the PARP market, we are adjusting our outlook to accommodate a slower adoption of Zejula, which is leading us to lower our target price from $199 to $122. We believe Zejula has the strongest data in the ovarian cancer maintenance setting and upside that could result from label expansion in other tumor types." (2/27/2018)
2. HC Wainwright analysts commented, "Updates to Varubi’s Label; Reiterate Buy and $158 Price Target Prescribing information update, no products being recalled. After the close on January 12, TESARO announced that it has updated the Varubi injectable emulsion package insert in collaboration with the FDA. The changes to the label include modifications to the Contradictions, Warnings and Precuations, and Adverse Reactions section to inclde anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions associated with the use of Varubi injectable emulsion. The company indicated that anaphylaxis, anaphylactic shock and other hypersensitivity reactions have been reported in the postmarketing setting, with some cases requiring hospitalization. These side effects were noted during or soon after the infusion of Varubi, with most reactions observed during the first few minutes of administration." (1/12/2018)
3. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (1/11/2018)
4. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
5. Cowen Inc analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)

Who are some of Tesaro's key competitors?

Some companies that are related to Tesaro include Ionis Pharmaceuticals (IONS), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), Blueprint Medicines (BPMC), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Advanced Accelerator Application (AAAP), Array Biopharma (ARRY), Clovis Oncology (CLVS) and Amicus Therapeutics (FOLD).

Who are Tesaro's key executives?

Tesaro's management team includes the folowing people:

Mr. Leon O. Moulder Jr., Co-Founder, Chief Exec. Officer and Director (Age 61)
Dr. Mary Lynne Hedley, Co-Founder, Pres, Chief Operating Officer and Director (Age 55)
Mr. Timothy R. Pearson, Chief Financial Officer and Exec. VP (Age 50)
Dr. Jeffrey H. Hanke Ph.D., Chief Scientific Officer and Exec. VP of R&D (Age 61)
Dr. Martin H. Huber Jr., M.D., Chief Medical Officer and Sr. VP (Age 58)

Has Tesaro been receiving favorable news coverage?

Headlines about TSRO stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tesaro earned a news sentiment score of 0.16 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 44.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Tesaro?

Shares of TSRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tesaro's stock price today?

One share of TSRO stock can currently be purchased for approximately $52.54.

How big of a company is Tesaro?

Tesaro has a market capitalization of $2.99 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. Tesaro employs 715 workers across the globe.

How can I contact Tesaro?

Tesaro's mailing address is 1000 WINTER STREET SUITE 3300, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.

MarketBeat Community Rating for Tesaro (TSRO)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		477 (Vote Outperform)
Underperform Votes:		306 (Vote Underperform)
Total Votes:		783

MarketBeat's community ratings are surveys of what our community members think about Tesaro and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Tesaro (NASDAQ:TSRO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

23 Wall Street analysts have issued ratings and price targets for Tesaro in the last 12 months. Their average twelve-month price target is $129.2609, suggesting that the stock has a possible upside of 149.88%. The high price target for TSRO is $199.00 and the low price target for TSRO is $48.00. There are currently 9 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.61	2.58	2.58	2.58
Ratings Breakdown:	0 Sell Rating(s) 9 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 10 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 10 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 10 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$129.2609	$131.4348	$148.7391	$169.8182
Price Target Upside:	149.88% upside	137.98% upside	134.23% upside	44.02% upside

Tesaro (NASDAQ:TSRO) Consensus Price Target History

Price Target History for Tesaro (NASDAQ:TSRO)

Tesaro (NASDAQ:TSRO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/27/2018	HC Wainwright	Reiterated Rating	Buy	$108.00	High
3/1/2018	Morgan Stanley	Lower Price Target	Overweight -> Overweight	$156.00 -> $146.00	Low
2/28/2018	Credit Suisse Group	Reiterated Rating	Outperform -> In-Line	$150.00 -> $141.00	High
2/28/2018	Wells Fargo	Reiterated Rating	Outperform	$224.00 -> $122.00	Medium
2/28/2018	Leerink Swann	Reiterated Rating	Outperform	$123.00 -> $105.00	High
2/28/2018	Royal Bank of Canada	Lower Price Target	Sector Perform	$48.00	High
2/28/2018	Barclays	Lower Price Target	Equal Weight -> Equal Weight	$135.00 -> $90.00	High
2/27/2018	Cann	Reiterated Rating	Buy	$199.00 -> $122.00	Medium
2/22/2018	Evercore ISI	Upgrade	In-Line -> Outperform	$88.00	High
1/18/2018	Piper Jaffray	Reiterated Rating	Hold	$65.00	Low
1/2/2018	Cowen	Lower Price Target	Market Perform	$125.00 -> $80.00	Low
12/20/2017	Citigroup	Reiterated Rating	Buy -> Buy	$216.00 -> $135.00	Low
11/28/2017	Argus	Set Price Target	Buy	$154.00	Low
11/10/2017	SunTrust Banks	Reiterated Rating	Buy	$160.00	N/A
11/10/2017	Robert W. Baird	Reiterated Rating	Hold	$120.00	N/A
11/9/2017	Lake Street Capital	Reiterated Rating	Buy	$143.00	N/A
11/3/2017	Jefferies Group	Reiterated Rating	Hold	$124.00	N/A
9/11/2017	Wedbush	Reiterated Rating	Outperform	$160.00	Low
9/10/2017	Oppenheimer	Reiterated Rating	Buy	$199.00	Low
7/14/2017	Janney Montgomery Scott	Reiterated Rating	Neutral		Low
7/7/2017	Gabelli	Initiated Coverage	Buy	$175.00	High
6/20/2017	Raymond James	Reiterated Rating	Market Perform		Medium
6/20/2017	Bank of America	Reiterated Rating	Buy	$154.00	High
6/5/2017	FBR & Co	Lower Price Target	Mkt Perform -> Mkt Perform	$200.00 -> $195.00	High
11/4/2016	UBS	Downgrade	Outperform -> Market Perform		N/A
8/5/2016	Mizuho	Lower Price Target	Buy	$100.00 -> $94.00	N/A

(Data available from 4/20/2016 forward)

Tesaro (NASDAQ:TSRO) Earnings History and Estimates Chart

Earnings by Quarter for Tesaro (NASDAQ:TSRO)

Tesaro (NASDAQ:TSRO) Earnings Estimates

2018 EPS Consensus Estimate: ($9.53)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	($3.15)	($2.52)	($2.85)
Q2 2018	5	($2.63)	($1.99)	($2.38)
Q3 2018	5	($2.74)	($1.68)	($2.26)
Q4 2018	5	($2.58)	($1.32)	($2.04)

Tesaro (NASDAQ TSRO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($2.56)					N/A
2/27/2018	Q4 2017	($2.39)	($3.35)	$51.78 million	$48.02 million	View	Listen
11/7/2017	Q3 2017	($1.16)	($0.4660)	$130.57 million	$142.77 million	View	N/A
8/8/2017	Q2 2017	($2.52)	($2.82)	$18.61 million	$29.50 million	View	Listen
5/9/2017	Q1 2017	($2.26)	($2.55)	$3.84 million	$3.10 million	View	Listen
2/28/2017	Q4 2016	($1.96)	($2.60)	$5.60 million	$4.23 million	View	N/A
11/3/2016	Q3	($1.92)	($1.98)	$4.39 million	$3.73 million	View	N/A
8/4/2016	Q2 2016	($1.69)	($1.28)	$10.49 million	$36.56 million	View	N/A
5/5/2016	Q1	($1.69)	($2.22)	$2.48 million	$0.31 million	View	N/A
2/25/2016	Q4	($1.63)	($1.89)	$3.45 million	$0.23 million	View	Listen
10/29/2015	Q315	($1.52)	($1.66)		$0.09 million	View	Listen
8/6/2015	Q215	($1.14)	($1.51)			View	Listen
4/30/2015	Q115	($1.12)	($1.30)			View	Listen
2/19/2015	Q414	($1.03)	($1.33)			View	Listen
11/5/2014	Q314	($1.04)	($1.01)			View	N/A
7/24/2014	Q214	($0.87)	($1.03)			View	N/A
4/30/2014	Q114	($1.06)	($1.43)			View	N/A
2/19/2014	Q413	($0.78)	($0.72)			View	N/A
11/7/2013	Q313	($0.69)	($0.88)			View	N/A
7/25/2013	Q2 2013	($0.63)	($0.67)			View	N/A
4/25/2013	Q1 2013	($0.62)	($0.66)			View	N/A
2/14/2013	Q4 2012	($0.65)	($15.41)			View	N/A
10/25/2012		($0.55)	($0.52)			View	N/A
7/26/2012		($0.55)	($4.11)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Tesaro (NASDAQ:TSRO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Tesaro (NASDAQ TSRO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.70%

Insider Trading History for Tesaro (NASDAQ:TSRO)

Institutional Ownership by Quarter for Tesaro (NASDAQ:TSRO)

Tesaro (NASDAQ TSRO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/8/2018	Orlando Oliveira	SVP	Sell	3,000	$69.88	$209,640.00	9,076
3/6/2018	Peter J Barris	Major Shareholder	Buy	145,532	$57.40	$8,353,536.80	252
3/5/2018	David M Mott	Director	Buy	61,437	$58.83	$3,614,338.71	12,825
3/2/2018	David M Mott	Director	Buy	68,302	$55.56	$3,794,859.12	12,825
3/2/2018	Enterprise Associates 13 L New	Major Shareholder	Buy	54,642	$55.56	$3,035,909.52	252
3/2/2018	Leon O Moulder Jr	CEO	Buy	5,000	$56.93	$284,650.00	1,018,828
3/2/2018	Martin H Jr. Huber	SVP	Sell	1,803	$54.86	$98,912.58	11,647
3/2/2018	Timothy R Pearson	CFO	Sell	2,575	$54.86	$141,264.50	7,303
3/1/2018	Grant C. Bogle	VP	Sell	1,809	$54.85	$99,223.65
3/1/2018	Mary Lynne Hedley	COO	Sell	3,855	$54.86	$211,485.30	16,073
12/4/2017	Martin H Jr. Huber	SVP	Sell	829	$85.24	$70,663.96	8,101
9/22/2017	Martin H Jr. Huber	SVP	Sell	592	$118.60	$70,211.20	6,943
9/18/2017	James O Armitage	Director	Sell	10,000	$117.13	$1,171,300.00	10,000
9/6/2017	Edward C English	VP	Sell	10,862	$134.92	$1,465,501.04	6,258
9/5/2017	Orlando Oliveira	SVP	Sell	71	$132.66	$9,418.86	6,626
9/1/2017	Grant C. Bogle	VP	Sell	14,167	$135.00	$1,912,545.00
6/6/2017	Edward C English	VP	Sell	8,500	$138.65	$1,178,525.00	5,396
4/3/2017	Martin H Jr. Huber	SVP	Sell	829	$153.02	$126,853.58	6,522
3/6/2017	Edward C English	VP	Sell	10,000	$178.06	$1,780,600.00	5,396
3/2/2017	Edward C English	VP	Sell	229	$177.61	$40,672.69	625
3/2/2017	Grant C. Bogle	SVP	Sell	1,447	$177.61	$257,001.67
3/2/2017	Mary Lynne Hedley	COO	Sell	3,927	$177.61	$697,474.47	10,000
1/3/2017	Martin H. Jr. Huber	SVP	Sell	190	$136.26	$25,889.40
11/2/2016	Martin H Jr. Huber	SVP	Sell	327	$121.29	$39,661.83	1,842
9/22/2016	Martin H Jr. Huber	SVP	Sell	408	$108.12	$44,112.96	1,250
9/8/2016	Edward C English	VP	Sell	7,000	$88.54	$619,780.00	3,500
8/30/2016	Jeffrey H Hanke	VP	Sell	29,166	$86.04	$2,509,442.64	29,166
6/30/2016	Jeffrey H Hanke	VP	Sell	12,500	$74.35	$929,375.00	12,500
6/10/2016	Edward C English	VP	Sell	7,000	$40.75	$285,250.00	3,500
3/18/2016	Arnold L Oronsky	Director	Buy	142,085	$35.19	$4,999,971.15	2,479
3/18/2016	Enterprise Associates 13 L New	Major Shareholder	Buy	710,429	$35.19	$24,999,996.51
3/10/2016	Edward C English	VP	Sell	7,000	$43.71	$305,970.00	3,500
12/10/2015	Edward C. English	VP	Sell	17,000	$50.19	$853,230.00
9/8/2015	James O Armitage	Director	Buy	500	$54.63	$27,315.00
12/12/2014	James O Armitage	Director	Buy	1,000	$38.16	$38,160.00
9/29/2014	Lawrence M Alleva	Director	Buy	1,100	$26.17	$28,787.00
7/31/2013	Lawrence M Alleva	Director	Buy	1,449	$34.33	$49,744.17
6/5/2013	Peter J Barris	Major Shareholder	Sell	3,583	$39.00	$139,737.00
4/30/2013	Lawrence M Alleva	Director	Buy	1,050	$28.10	$29,505.00
11/1/2012	Lawrence M Alleva	Director	Buy	3,240	$15.45	$50,058.00
8/30/2012	Leon O Moulder Jr	CEO	Buy	10,000	$11.69	$116,900.00

(Data available from 1/1/2013 forward)

Tesaro (NASDAQ TSRO) News Headlines

Source:

Date	Headline
	TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018 finance.yahoo.com - April 19 at 5:40 PM
	Tesaro Sees Unusually Large Options Volume (TSRO) www.americanbankingnews.com - April 18 at 7:02 AM
	Tesaro Sees Unusually High Options Volume (TSRO) www.americanbankingnews.com - April 18 at 7:02 AM
	ValuEngine Lowers Tesaro (TSRO) to Sell www.americanbankingnews.com - April 17 at 10:21 PM
	Tesaro (TSRO) Rating Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - April 17 at 12:21 PM
	Today’s Research Reports on Trending Tickers: Bristol-Myers Squibb and TESARO finance.yahoo.com - April 17 at 8:26 AM
	TESARO (TSRO) Reports Summarized Initial Data from Phase 1 GARNET trial of TSR-042 (anti-PD-1 antibody) www.streetinsider.com - April 16 at 5:28 PM
	BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR www.reuters.com - April 16 at 9:15 AM
	TESARO Summarizes TSR-042 Clinical Data Presented at AACR globenewswire.com - April 16 at 9:15 AM
	Tesaro Expected to Earn FY2020 Earnings of ($1.94) Per Share (TSRO) www.americanbankingnews.com - April 16 at 3:03 AM
	Tesaro (TSRO) Expected to Post Quarterly Sales of $56.68 Million www.americanbankingnews.com - April 15 at 3:45 AM
	Tesaro: Time To Buy seekingalpha.com - April 13 at 5:25 PM
	Tesaro (TSRO) Expected to Post Earnings of -$2.77 Per Share www.americanbankingnews.com - April 13 at 3:24 PM
	BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel www.reuters.com - April 13 at 8:33 AM
	Tesaro (TSRO) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - April 12 at 7:43 PM
	Tesaro's (TSRO) "Overweight" Rating Reiterated at Morgan Stanley www.americanbankingnews.com - April 11 at 5:35 PM
	TESARO (TSRO) Announces Exclusive Distribution Agreement with Medison Pharma to Commercialize ZEJULA in Israel www.streetinsider.com - April 11 at 8:42 AM
	TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel finance.yahoo.com - April 11 at 8:42 AM
	Tesaro (TSRO) Downgraded to "Sell" at ValuEngine www.americanbankingnews.com - April 7 at 8:19 PM
	Tesaro (TSRO) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - April 6 at 9:50 PM
	Tesaro (TSRO) Given Neutral Rating at Piper Jaffray www.americanbankingnews.com - April 6 at 12:11 PM
	Barclays Begins Coverage on Tesaro (TSRO) www.americanbankingnews.com - April 6 at 10:58 AM
	Zacks Investment Research Upgrades TESARO (TSRO) to "Hold" www.americanbankingnews.com - April 1 at 7:24 AM
	TESARO (TSRO) Stock Rating Reaffirmed by Piper Jaffray www.americanbankingnews.com - March 31 at 12:54 PM
	TESARO (TSRO) Given New $80.00 Price Target at Cowen www.americanbankingnews.com - March 31 at 11:47 AM
	Zacks: Brokerages Anticipate TESARO Inc (TSRO) Will Announce Quarterly Sales of $57.59 Million www.americanbankingnews.com - March 29 at 4:55 AM
	Morgan Stanley Remains Bullish on TESARO (TSRO) www.streetinsider.com - March 28 at 5:19 PM
	Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data seekingalpha.com - March 28 at 8:03 AM
	Tesaro Wants a Stronger Grip in Ovarian Cancer finance.yahoo.com - March 28 at 8:02 AM
	Brokerages Expect TESARO Inc (TSRO) Will Announce Earnings of -$2.77 Per Share www.americanbankingnews.com - March 27 at 3:18 PM
	TESARO (TSRO) Earns "Buy" Rating from HC Wainwright www.americanbankingnews.com - March 27 at 10:07 AM
	Technical Perspectives on Biotech Stocks -- Tesaro, Trevena, Vanda Pharma, and Verastem www.prnewswire.com - March 27 at 8:14 AM
	TESARO (TSRO): TOPACIO As Expected - Piper Jaffray www.streetinsider.com - March 27 at 8:14 AM
	Analyzing TESARO (TSRO) and Cytori Therapeutics (CYTX) www.americanbankingnews.com - March 27 at 8:09 AM
	TESARO (TSRO) Raised to Sell at BidaskClub www.americanbankingnews.com - March 26 at 10:58 PM
	TESARO (TSRO) Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in ... www.streetinsider.com - March 26 at 5:29 PM
	TESARO's Zejula + Merck's Keytruda shows positive effect in platinum-resistant ovarian cancer; shares up 2% after hours seekingalpha.com - March 26 at 5:29 PM
$Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer$	Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer finance.yahoo.com - March 26 at 5:29 PM
	Credit Suisse Reiterates Outperform on TESARO (TSRO) Ahead of SGO Conference www.streetinsider.com - March 26 at 9:13 AM
	DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders of Tesaro, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2018 - TSRO finance.yahoo.com - March 19 at 5:28 PM
	FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Tesaro, Inc. (TSRO) and Lead Plaintiff Deadline - March 19, 2018 finance.yahoo.com - March 19 at 5:28 PM
	DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against TESARO, Inc. And Reminds Investors with Losses Exceeding $100,000 to Contact the Firm finance.yahoo.com - March 19 at 5:28 PM
	TESARO Inc (TSRO) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - March 18 at 7:42 PM
	TESARO (TSRO) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - March 18 at 4:24 PM
	FINAL DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against TESARO, Inc. And Reminds Investors with Losses Exceeding $100,000 to Contact the Firm finance.yahoo.com - March 17 at 9:23 AM
	TESARO Announces Data Presentations at the 2018 American Association for Cancer Research Annual Meeting - GlobeNewswire (press release) globenewswire.com - March 16 at 5:40 PM
	Rosen Law Firm Reminds TESARO, Inc. Investors of Important March 19 Deadline in Class Action– TSRO - GlobeNewswire (press release) globenewswire.com - March 16 at 5:40 PM
	Rosen Law Firm Reminds TESARO, Inc. Investors of Important March 19 Deadline in Class Action– TSRO finance.yahoo.com - March 16 at 5:40 PM
	3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against TESARO, Inc. And Reminds Investors with Losses Exceeding $100,000 to Contact the Firm finance.yahoo.com - March 16 at 5:40 PM
	TSRO DEADLINE MONDAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Tesaro, Inc. and a Lead Plaintiff Deadline of March 19, 2018 (TSRO) finance.yahoo.com - March 16 at 5:40 PM

Tesaro (NASDAQ:TSRO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Tesaro (NASDAQ:TSRO) Income Statement, Balance Sheet and Cash Flow Statement

Tesaro (NASDAQ TSRO) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff